11633 RESULTS
COMMENT Increasing attention has been focused on the role of LXR in neurodegeneration. LXR is a transcription factor whose activity is controlled by the class of cholesterol catabolites termed oxysterols. LXR regulates many genes relevant to lipid metabolism incl
COMMENT Comment by Pat McGeer and Andis Klegeris Ramirez et al., in their paper on prevention of Alzheimer
COMMENT Factors that influence BACE activity are receiving increasing attention as it becomes clear that, compared to γ-secretase inhibition, BACE inhibition may be accomplished with relatively few side effects. In this paper, Jun Xie and Qing Guo expand on previ
COMMENT The paper by Cole and colleagues is a very elegant manuscript because it provides important new insights into how statins might affect APP processing. The observation that inhibition of isoprenoid metabolism increases intracellular Aβ accumulation is surp
COMMENT Infants and young children are subjected to a battery of infectious agents, including human herpes virus 6, herpes simplex virus type 1 (HSV1), adenoviruses, respiratory syncytial virus, rhinoviruses and probably enteroviruses, and these, as well as overt
COMMENT This paper by Stokin et al. from the lab of Larry Goldstein has some interesting and important findings. I think the finding that APPsw transgenics having half the dose of kinesin-1 have increased Aβ deposition and pathology strongly argues that normal ax
COMMENT Considering data from Ramírez et al. (2005), we can effectively conclude that the endocannabinoid system may be a promising therapeutic target in Alzheimer disease (AD). This report shows the first functional evidence on neuroprotective effects of CB1 and
COMMENT This is probably the best paper on the subject I have seen yet. If CB1 receptors in the brain could be utilized in programmed cell death we could have a brilliant first step in finding a cure for AD. And since antibodies and complement proteins are involv
COMMENT Have you considered the possibility that a mechanism of statin action in AD may be related to its stimulatory effect on cerebral blood flow? jimsylcr 0
COMMENT Are we looking under the lamp post? Blood is a complex system with many components. Although it is likely correct that plasma proteomics may provide a biomarker, will it be optimal and what new information may it reveal about the fundamental biology of AD
COMMENT This paper is most remarkable. The authors show that statin treatment, which has long been thought to be beneficial for Alzheimer disease patients, has two independent and diverging effects on APP processing. In a novel in-vitro system, the authors have b
COMMENT The paper by Stokin et al is most remarkable and very convincing. Reducing axonal transport enhanced axonopathy, increased intracellular Aβ levels and extracellular deposition. Stimulation of APP cleavage may be the consequence of enhanced presence of APP
COMMENT Building on their earlier provocative findings linking APP function to fast axonal transport, Stokin and colleagues, in this latest report, reinforce several important themes that are emerging from recent studies. First, significant neuronal pathobiology,
COMMENT This is an excellent paper and it markedly focuses on the importance of both reactive gliosis and the cannabinoid receptor involvement in Alzheimer disease. Targeting reactive gliosis may represent a new, promising approach to inhibit progression of Alzhe
COMMENT My speculations about AD include the thought that AD has an extremely long presymptomatic period, which may extend into childhood. This is based on data such as the Braaks finding that 20 percent of people in their 20s have neurofibrillary tangles (NFT) a
